Literature DB >> 4032435

New cysteamine (2-chloroethyl)nitrosoureas. Synthesis and preliminary antitumor results.

J C Madelmont, D Godeneche, D Parry, J Duprat, J L Chabard, R Plagne, G Mathe, G Meyniel.   

Abstract

Three chemical pathways were used for the synthesis of four new N'-(2-chloroethyl)-N-[2-(methylsulfinyl)ethyl]- and N'-(2-chloroethyl)-N-[2-(methylsulfonyl)ethyl]-N- or N'-nitrosoureas. These compounds are plasma metabolites of CNCC, a promising antineoplastic (2-chloroethyl)nitrosourea. Preliminary antitumor evaluation was performed against L1210 leukemia implanted intraperitoneally in mice. Among these compounds, two of them exhibited a greater antitumor activity compared to that of the parent mixture.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4032435     DOI: 10.1021/jm00147a040

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  4 in total

1.  Phase II trial of cystemustine, a new nitrosourea, as treatment of high-grade brain tumors in adults.

Authors:  H Roche; H Cure; A Adenis; P Fargeot; C Terret; M A Lentz; J C Madelmont; P Fumoleau; A Hanausk; P Chollet
Journal:  J Neurooncol       Date:  2000-09       Impact factor: 4.130

2.  Cystemustine in recurrent high grade glioma.

Authors:  X Durando; E Thivat; H Roché; J O Bay; J-J Lemaire; P Verrelle; M-A Lentz; J Chazal; H Curé; P Chollet
Journal:  J Neurooncol       Date:  2006-03-31       Impact factor: 4.130

3.  Cytostatic action of two nitrosoureas derived from cysteamine.

Authors:  C Bourut; E Chenu; D Godenèche; J C Madelmont; R Maral; G Mathé; G Meyniel
Journal:  Br J Pharmacol       Date:  1986-11       Impact factor: 8.739

4.  Enhancement by O6-benzyl-N2-acetylguanosine of N'-[2-chloroethyl]-N-[2-(methylsulphonyl)ethyl]-N'-nitrosourea therapeutic index on nude mice bearing resistant human melanoma.

Authors:  E Debiton; C Cussac-Buchdhal; E Mounetou; M Rapp; J M Dupuy; J C Maurizis; A Veyre; J C Madelmont
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.